NEWS & MEDIA

Image Alt Text

NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CLINICAL DEVELOPMENT INTO PHASE III

THE BIOLOGICAL OBJECTIVE AND THREE OUT OF FOUR CLINICAL OBJECTIVES WERE MET:

  • Highly statistically significant efficacy in reduction of interferon signature
  • Lack of statistically significant clinical efficacy measured by BICLA[1]score
  • Statistical trend on clinical efficacy measured by SRI-4[2]  with reduction of steroid less than or equal to 5mg/day
  • Statistically significant clinical efficacy on the LLDAS[3] score
  • Favorable safety profile of IFNalpha Kinoid treatment

 

Read More

NEOVACS ANNOUNCES TWO APPOINTMENTS TO ITS EXECUTIVE COMMITTEE...

Paris & Boston, February 20th, 2019 – 07h30 CET – Néovacs (Euronext Growth Paris: ALNEV), leader...

NEOVACS TO HOST KOL MEETING TO DISCUSS ITS THERAPEUTIC VACCINE...

Paris and Boston, February 5th 2019 – 7h30 CET – Neovacs (Euronext Growth Paris: ALNEV), leader in active...

NEOVACS ANNOUNCES ITS CLINICAL ADVISORY BOARD MEETING TO...

Paris and Boston, January 31th, 2019 – 5:45 pm CET – Neovacs (Euronext Paris Growth Paris: ALNEV),...

NÉOVACS TO PRESENT FULL RESULTS FROM THE PHASE IIb IFNα...

Paris & Boston, January 24th, 2019 – 17:45 pm CET – Neovacs (Euronext Growth Paris: ALNEV), leader in...

NEOVACS SECURES FINANCING FROM THE ANR TO DEVELOP THE...

Paris and Boston, January 8, 2019 – 7:30 CET – Neovacs (Euronext Paris Growth Paris: ALNEV), leader in...